Your browser doesn't support javascript.
loading
Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.
Mojica, Maria F; Papp-Wallace, Krisztina M; Taracila, Magdalena A; Barnes, Melissa D; Rutter, Joseph D; Jacobs, Michael R; LiPuma, John J; Walsh, Thomas J; Vila, Alejandro J; Bonomo, Robert A.
Afiliación
  • Mojica MF; Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Papp-Wallace KM; Research Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA.
  • Taracila MA; Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Barnes MD; Research Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA.
  • Rutter JD; Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Jacobs MR; Research Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA.
  • LiPuma JJ; Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Walsh TJ; Research Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA.
  • Vila AJ; Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Bonomo RA; Research Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Antimicrob Agents Chemother ; 61(10)2017 10.
Article en En | MEDLINE | ID: mdl-28784669
Stenotrophomonas maltophilia is an emerging opportunistic pathogen, classified by the World Health Organization as one of the leading multidrug-resistant organisms in hospital settings. The need to discover novel compounds and/or combination therapies for S. maltophilia is urgent. We demonstrate the in vitro efficacy of aztreonam-avibactam (ATM-AVI) against S. maltophilia and kinetically characterize the inhibition of the L2 ß-lactamase by avibactam. ATM-AVI overcomes aztreonam resistance in selected clinical strains of S. maltophilia, addressing an unmet medical need.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 Problema de salud: 2_cobertura_universal Asunto principal: Beta-Lactamasas / Aztreonam / Stenotrophomonas maltophilia / Compuestos de Azabiciclo / Inhibidores de beta-Lactamasas / Antibacterianos Límite: Humans Idioma: En Revista: Antimicrob Agents Chemother Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 Problema de salud: 2_cobertura_universal Asunto principal: Beta-Lactamasas / Aztreonam / Stenotrophomonas maltophilia / Compuestos de Azabiciclo / Inhibidores de beta-Lactamasas / Antibacterianos Límite: Humans Idioma: En Revista: Antimicrob Agents Chemother Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos